Article | Published:

Large-scale prediction and testing of drug activity on side-effect targets

Nature volume 486, pages 361367 (21 June 2012) | Download Citation

Abstract

Discovering the unintended ‘off-targets’ that predict adverse drug reactions is daunting by empirical methods alone. Drugs can act on several protein targets, some of which can be unrelated by conventional molecular metrics, and hundreds of proteins have been implicated in side effects. Here we use a computational strategy to predict the activity of 656 marketed drugs on 73 unintended ‘side-effect’ targets. Approximately half of the predictions were confirmed, either from proprietary databases unknown to the method or by new experimental assays. Affinities for these new off-targets ranged from 1 nM to 30 μM. To explore relevance, we developed an association metric to prioritize those new off-targets that explained side effects better than any known target of a given drug, creating a drug–target–adverse drug reaction network. Among these new associations was the prediction that the abdominal pain side effect of the synthetic oestrogen chlorotrianisene was mediated through its newly discovered inhibition of the enzyme cyclooxygenase-1. The clinical relevance of this inhibition was borne out in whole human blood platelet aggregation assays. This approach may have wide application to de-risking toxicological liabilities in drug discovery.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. When good drugs go bad. Nature 446, 975–977 (2007)

  2. 2.

    Trial watch: phase III and submission failures: 2007–2010. Nature Rev. Drug Discov. 10, 87 (2011)

  3. 3.

    Trial watch: phase II failures: 2008–2010. Nature Rev. Drug Discov. 10, 328–329 (2011)

  4. 4.

    The use of computer models in pharmaceutical safety evaluation. Altern. Lab. Anim. 37, 467–475 (2009)

  5. 5.

    , , & Cardiovascular hazard and non-steroidal anti-inflammatory drugs. Curr. Opin. Pharmacol. 5, 204–210 (2005)

  6. 6.

    et al. Protein adducts as prospective biomarkers of nevirapine toxicity. Chem. Res. Toxicol. 23, 1714–1725 (2010)

  7. 7.

    et al. Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102, 2836–2841 (2000)

  8. 8.

    , & HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation 94, 817–823 (1996)

  9. 9.

    et al. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80, 795–803 (1995)

  10. 10.

    et al. Drug Adverse Reaction Target Database (DART): proteins related to adverse drug reactions. Drug Saf. 26, 685–690 (2003)

  11. 11.

    , , , & A side effect resource to capture phenotypic effects of drugs. Mol. Syst. Biol. 6, 343 (2010)

  12. 12.

    & Prediction of drug-related cardiac adverse effects in humans–A: Creation of a database of effects and identification of factors affecting their occurrence. Regul. Toxicol. Pharmacol. 56, 247–275 (2010)

  13. 13.

    et al. Kinase inhibition-related adverse events predicted from in vitro kinome and clinical trial data. J. Biomed. Inform. 43, 376–384 (2010)

  14. 14.

    Network pharmacology: the next paradigm in drug discovery. Nature Chem. Biol. 4, 682–690 (2008)

  15. 15.

    et al. DITOP: drug-induced toxicity related protein database. Bioinformatics 23, 1710–1712 (2007)

  16. 16.

    , , , & SePreSA: a server for the prediction of populations susceptible to serious adverse drug reactions implementing the methodology of a chemical-protein interactome. Nucleic Acids Res. 37, W406–W412 (2009)

  17. 17.

    , , & Building the process-drug-side effect network to discover the relationship between biological processes and side effects. BMC Bioinformatics 12 (suppl. 2). S2 (2011)

  18. 18.

    & Protein binding specificity versus promiscuity. Curr. Opin. Struct. Biol. 21, 50–61 (2011)

  19. 19.

    et al. Associating drugs, targets and clinical outcomes into an integrated network affords a new platform for computer-aided drug repurposing. Mol. Inform. 30, 100–111 (2011)

  20. 20.

    , , , & Global mapping of pharmacological space. Nature Biotechnol. 24, 805–815 (2006)

  21. 21.

    et al. Mapping adverse drug reactions in chemical space. J. Med. Chem. 52, 3103–3107 (2009)

  22. 22.

    et al. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. ChemMedChem 2, 861–873 (2007)

  23. 23.

    , , , & Drug target identification using side-effect similarity. Science 321, 263–266 (2008)

  24. 24.

    et al. Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels. Clin. Pharmacol. Ther. 90, 133–142 (2011)

  25. 25.

    et al. Predicting new molecular targets for known drugs. Nature 462, 175–181 (2009)

  26. 26.

    et al. Relating protein pharmacology by ligand chemistry. Nature Biotechnol. 25, 197–206 (2007)

  27. 27.

    , , , & Quantifying the relationships among drug classes. J. Chem. Inf. Model. 48, 755–765 (2008)

  28. 28.

    et al. Modeling promiscuity based on in vitro safety pharmacology profiling data. ChemMedChem 2, 874–880 (2007)

  29. 29.

    et al. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 40, D1100–D1107 10.1093/nar/gkr777. (2012)

  30. 30.

    et al. Chemical informatics and target identification in a zebrafish phenotypic screen. Nature Chem. Biol. 8, 144–146 (2012)

  31. 31.

    et al. Epik: a software program for pKa prediction and protonation state generation for drug-like molecules. J. Comput. Aided Mol. Des. 21, 681–691 (2007)

  32. 32.

    et al. Application of belief theory to similarity data fusion for use in analog searching and lead hopping. J. Chem. Inf. Model. 48, 941–948 (2008)

  33. 33.

    , , , & Drug–target network. Nature Biotechnol. 25, 1119–1126 (2007)

  34. 34.

    & Role of dopamine transporter imaging in the diagnosis of atypical tremor disorders. Mov. Disord. 18 (suppl. 7). S22–S27 (2003)

  35. 35.

    , & Inhibition of Na+ current by diphenhydramine and other diphenyl compounds: molecular determinants of selective binding to the inactivated channels. Mol. Pharmacol. 57, 135–143 (2000)

  36. 36.

    & Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Am. J. Med. 86, 449–458 (1989)

  37. 37.

    , , , & Prevalence and cost of hospitalization for gastrointestinal complications related to peptic ulcers with bleeding or perforation: comparison of two national databases. Am. J. Manag. Care 4, 399–409 (1998)

  38. 38.

    , , , & Selective COX-1 inhibition: A therapeutic target to be reconsidered. Curr. Med. Chem. 17, 3769–3805 (2010)

  39. 39.

    , , , & The effects of estrone, estradiol and estriol on platelet aggregation induced by adrenaline and adenosine diphosphate. Platelets 17, 441–447 (2006)

  40. 40.

    & Effect of oestrogen dose on whole blood platelet activation in women taking new low dose oral contraceptives. Thromb. Haemost. 72, 926–930 (1994)

  41. 41.

    & The influence of drug-like concepts on decision-making in medicinal chemistry. Nature Rev. Drug Discov. 6, 881–890 (2007)

  42. 42.

    , , & Pharmacological promiscuity: dependence on compound properties and target specificity in a set of recent Roche compounds. ChemMedChem 4, 680–686 (2009)

  43. 43.

    et al. Cytokine-associated drug toxicity in human hepatocytes is associated with signaling network dysregulation. Mol. Biosyst. 6, 1195–1206 (2010)

  44. 44.

    , , & Data completeness–the Achilles heel of drug-target networks. Nature Biotechnol. 26, 983–984 (2008)

  45. 45.

    , , & The topology of drug-target interaction networks: implicit dependence on drug properties and target families. Mol. Biosyst. 5, 1051–1057 (2009)

  46. 46.

    & Extended-connectivity fingerprints. J. Chem. Inf. Model. 50, 742–754 (2010)

  47. 47.

    , & Daylight Theory Manual — Daylight 4.91 (Daylight Chemical Information Systems, 2005)

  48. 48.

    et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 36, D901–D906 (2008)

  49. 49.

    , & An open standard for chemical structure representation — the IUPAC chemical identifier. Nimes Int. Chem. Inf. Conf. Proc. 143, 131–143 (2003)

  50. 50.

    The UniProt Consortium. Ongoing and future developments at the Universal Protein Resource. Nucleic Acids Res. 39, D214–D219 (2010)

  51. 51.

    et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25, 3389–3402 (1997)

  52. 52.

    , & The medical dictionary for regulatory activities (MedDRA). Drug Saf. 20, 109–117 (1999)

  53. 53.

    & Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B 57, 289–300 (1995)

Download references

Acknowledgements

E.L. is a presidential postdoctoral fellow supported by the Education Office of the Novartis Institutes for Biomedical Research (co-mentors L.U. and B.K.S.). Supported by US National Institutes of Health grants GM71896 (to B.K.S. and J. Irwin), AG002132 (to S. Prusiner and B.K.S.), and GM93456 (to M.J.K.), and by QB3 Rogers Family Foundation ‘Bridging-the-Gap’ Award (to M.J.K.).

Author information

Author notes

    • Eugen Lounkine
    •  & Michael J. Keiser

    These authors contributed equally to this work.

Affiliations

  1. Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139, USA

    • Eugen Lounkine
    • , Steven Whitebread
    • , Dmitri Mikhailov
    • , Jeremy L. Jenkins
    •  & Laszlo Urban
  2. SeaChange Pharmaceuticals Inc, 409 Illinois Street, San Francisco, California 94158, USA

    • Michael J. Keiser
  3. Department of Pharmaceutical Chemistry, University of California, San Francisco, 1700 4th Street, Byers Hall Suite 508D, California 94158-2550, USA

    • Michael J. Keiser
    • , Allison K. Doak
    •  & Brian K. Shoichet
  4. Novartis Institutes for Biomedical Research, 4056 Basel, Switzerland

    • Jacques Hamon
    • , Paul Lavan
    • , Eckhard Weber
    •  & Serge Côté

Authors

  1. Search for Eugen Lounkine in:

  2. Search for Michael J. Keiser in:

  3. Search for Steven Whitebread in:

  4. Search for Dmitri Mikhailov in:

  5. Search for Jacques Hamon in:

  6. Search for Jeremy L. Jenkins in:

  7. Search for Paul Lavan in:

  8. Search for Eckhard Weber in:

  9. Search for Allison K. Doak in:

  10. Search for Serge Côté in:

  11. Search for Brian K. Shoichet in:

  12. Search for Laszlo Urban in:

Contributions

SEA calculations were undertaken by M.J.K. Target–ADR associations, networks and promiscuity analysis were by E.L. In vitro assays were directed by S.W., J.H. and L.U. PK and PD experiments were conducted by E.W. and P.L. Platelet aggregation study was designed and carried out by L.U. and S.C. Chlorotrianisene solubility and aggregation were conducted by A.K.D. The project was conceived and planned by B.K.S., J.J., D.M. and L.U. Overall analysis and writing was largely by E.L., M.J.K., B.K.S. and L.U. All authors contributed to the manuscript.

Competing interests

B.K.S. is a founder of SeaChange Pharmaceuticals Inc, a company that uses the SEA technology. The other authors have no competing interests to declare.

Corresponding authors

Correspondence to Jeremy L. Jenkins or Brian K. Shoichet or Laszlo Urban.

Supplementary information

PDF files

  1. 1.

    Supplementary Information

    This file contains Supplementary Methods, Supplementary Results, Supplementary References, Supplementary Figure 1 and legends for Supplementary Tables 1-8 (see separate file for tables).

Excel files

  1. 1.

    Supplementary Tables

    This file contains Supplementary Tables 1-8 (see Supplementary Information file for legends). Each sheet in the workbook corresponds to one table.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nature11159

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.